These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. Yuthavong Y; Vilaivan T; Chareonsethakul N; Kamchonwongpaisan S; Sirawaraporn W; Quarrell R; Lowe G J Med Chem; 2000 Jul; 43(14):2738-44. PubMed ID: 10893311 [TBL] [Abstract][Full Text] [Related]
23. Exploring QSAR, pharmacophore mapping and docking studies and virtual library generation for cycloguanil derivatives as PfDHFR-TS inhibitors. Ojha PK; Roy K Med Chem; 2011 May; 7(3):173-99. PubMed ID: 21486210 [TBL] [Abstract][Full Text] [Related]
24. Application of molecular docking and PSO-SVR intelligent approaches in antimalarial activity prediction of enantiomeric cycloguanil analogues. Inthajak K; Toochinda P; Lawtrakul L SAR QSAR Environ Res; 2018 Dec; 29(12):957-974. PubMed ID: 30381963 [TBL] [Abstract][Full Text] [Related]
26. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. Kamchonwongpaisan S; Quarrell R; Charoensetakul N; Ponsinet R; Vilaivan T; Vanichtanankul J; Tarnchompoo B; Sirawaraporn W; Lowe G; Yuthavong Y J Med Chem; 2004 Jan; 47(3):673-80. PubMed ID: 14736247 [TBL] [Abstract][Full Text] [Related]
27. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. Sirichaiwat C; Intaraudom C; Kamchonwongpaisan S; Vanichtanankul J; Thebtaranonth Y; Yuthavong Y J Med Chem; 2004 Jan; 47(2):345-54. PubMed ID: 14711307 [TBL] [Abstract][Full Text] [Related]
28. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304 [TBL] [Abstract][Full Text] [Related]
29. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents. Keenan SM; Welsh WJ J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982 [TBL] [Abstract][Full Text] [Related]
37. Metalloantimalarials: synthesis, X-ray crystal structure of potent antimalarial copper (II) complex of arylazo-4-hydroxy-1,2-naphthoquinone. Gokhale NH; Shirisha K; Padhye SB; Croft SL; Kendrick HD; Mckee V Bioorg Med Chem Lett; 2006 Jan; 16(2):430-2. PubMed ID: 16275074 [TBL] [Abstract][Full Text] [Related]
38. Characterization of dihydrofolate reductases from multiple strains of Plasmodium falciparum using mathematical descriptors of their inhibitors. Basak SC; Mills D; Hawkins DM Chem Biodivers; 2011 Mar; 8(3):440-53. PubMed ID: 21404427 [TBL] [Abstract][Full Text] [Related]
39. Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities. Thakkar SS; Thakor P; Ray A; Doshi H; Thakkar VR Bioorg Med Chem; 2017 Oct; 25(20):5396-5406. PubMed ID: 28789907 [TBL] [Abstract][Full Text] [Related]
40. Conformationally restrained aromatic analogues of fosmidomycin and FR900098. Kurz T; Schlüter K; Pein M; Behrendt C; Bergmann B; Walter RD Arch Pharm (Weinheim); 2007 Jul; 340(7):339-44. PubMed ID: 17611943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]